Tumor DNA in blood during surgery may predict pancreatic cancer outcomes

NCT ID NCT06478056

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 40 patients with pancreatic cancer to measure circulating tumor DNA (ctDNA) in blood from a vein near the pancreas and in the arm, as well as in fluid from the belly, during surgery. The goal was to see if these DNA levels could help predict how the disease progresses. The study is complete and focused on understanding the disease better, not on testing a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors better predict outcomes for pancreatic cancer patients by using tumor DNA levels during surgery.

What could go wrong

This is a small, completed observational study, not a treatment trial. The findings may not lead to immediate clinical changes or apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital, Rouen

    Rouen, 76031, France